These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1902448)

  • 1. Antigen-presenting cells constitutively bind tumor antigens in the tumor-bearing state in vivo to construct an effective immunogenic unit.
    Shimizu J; Zou JP; Ikegame K; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1991 Mar; 82(3):262-5. PubMed ID: 1902448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
    Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
    J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity.
    Zou JP; Shimizu J; Ikegame K; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Immunol; 1992 Jan; 148(2):648-55. PubMed ID: 1345922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Hamaoka T; Shimizu J; Suda T; Fujiwara H
    Princess Takamatsu Symp; 1988; 19():265-75. PubMed ID: 3269360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.
    Zou JP; Nagata T; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Cancer Res Clin Oncol; 1994; 120(5):279-85. PubMed ID: 7907334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Shimizu J; Suda T; Yoshioka T; Kosugi A; Fujiwara H; Hamaoka T
    J Immunol; 1989 Feb; 142(3):1053-9. PubMed ID: 2464022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific T cell lines: capacity to proliferate and produce interleukin 2 in response to various forms of tumor antigens.
    Shimizu J; Suda T; Katagiri T; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1992 Feb; 83(2):184-93. PubMed ID: 1372887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.
    Nagata T; Zou JP; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1993 Nov; 84(11):1181-9. PubMed ID: 7903964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.
    Zou JP; Shimizu J; Ikegame K; Takiuchi H; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1992; 35(1):1-6. PubMed ID: 1611618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.
    Ogawa M; Tsutsui T; Zou JP; Mu J; Wijesuriya R; Yu WG; Herrmann S; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Jun; 57(11):2216-22. PubMed ID: 9187124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro.
    Lynch DH; Gurish MF; Daynes RA
    Immunology; 1982 Sep; 47(1):49-59. PubMed ID: 6981587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens.
    Kruisbeek AM; Titus JA; Stephany DA; Gause BL; Longo DL
    J Immunol; 1985 Jun; 134(6):3605-14. PubMed ID: 2580891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfunction of Ia-positive antigen-presenting cells in tumor-bearing mice.
    Yamashita U
    Jpn J Cancer Res; 1987 Mar; 78(3):261-9. PubMed ID: 3106282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of xenogenized vaccine cells in vivo.
    Graf N; Adam C; Mocikat R
    Int J Cancer; 2003 Jun; 105(2):217-20. PubMed ID: 12673682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells.
    Aberer W; Kruisbeek AM; Shimada S; Katz SI
    J Immunol; 1986 Feb; 136(3):830-6. PubMed ID: 3455705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
    Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
    J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function.
    Kruisbeek AM; Mond JJ; Fowlkes BJ; Carmen JA; Bridges S; Longo DL
    J Exp Med; 1985 May; 161(5):1029-47. PubMed ID: 3921649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.